DNLI 13.74 (+11.8%)
US24823R1059BiotechnologyBiotechnology

Denali Therapeutics (DNLI) Stock Highlights

13.74 | +11.8%
2025-04-03 03:46:25
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The companys development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinsons disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Statistics

Range Today
12.07 14.83
Volume Today 3.63M
Range 1 Year
12.05 33.33
Volume 1 Year 261.94M
Range 3 Year
12.05 39.43
Volume 3 Year 658.81M
Range 10 Year
12.05 93.94
Volume 10 Year 1.2B

Highlights

Market Capitalization 2.15B (mid)
Floating Shares 131.34M
Current Price 13.74
Price To Earnings -5.5
Price To Book 1.73
Earnings Per Share -2.57
Payout Ratio 0%

Performance

Latest +11.8%
1 Month -16.01%
3 Months -33.72%
6 Months -51.57%
1 Year -31.37%
3 Years -61.04%
5 Years -13.2%
10 Years -36.24%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.